Effect of Eplerenone on Endothelial Function in Patients With Stable Coronary Heart Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00427284|
Recruitment Status : Completed
First Posted : January 29, 2007
Last Update Posted : December 23, 2011
The aim of the present study is to investigate wether endothelial dysfunction associated with stable coronary artery disease is altered by selective aldosterone antagonism with Eplerenone as potential anti-inflammatory drug versus placebo.
Additionally we hypothesize that selective aldosterone antagonism reduces systemic inflammatory response such as C-reactive proteine, oxidative stress and pro-inflammatory cytokines.
|Condition or disease|
|Coronary Artery Disease|
|Study Type :||Observational|
|Actual Enrollment :||42 participants|
|Observational Model:||Case Control|
|Study Start Date :||July 2004|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00427284
|University Hospital Zurich, Division of Cardiology|
|Zurich, ZH, Switzerland, 8091|
|Principal Investigator:||Frank Ruschitzka, Prof MD||University Hospital Zurich, Division of Cardiology|